Page 1791 - Williams Hematology ( PDFDrive )

1766 Part XI: Malignant Lymphoid Diseases Chapter 107: Myeloma 1767

263. Zangari M, Elice F, Fink L, et al: Hemostatic dysfunction in paraproteinemias and amy- 292. Greipp PR, Leong T, Bennett JM, et al: Plasmablastic morphology—An independent
loidosis. Semin Thromb Hemost 33:339–349, 2007. prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncol-
264. Deitcher SR, Erban JK, Limentani SA: Acquired free protein S deficiency associated ogy Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory
with multiple myeloma: A case report. Am J Hematol 51:319–323, 1996. Group. Blood 91:2501–2507, 1998.
265. Gruber A, Blasko G, Sas G: Functional deficiency of protein C and skin necrosis in 293. Greipp PR, Raymond NM, Kyle RA, et al: Multiple myeloma: Significance of plasmab-
multiple myeloma. Thromb Res 42:579–581, 1986. lastic subtype in morphological classification. Blood 65:305–310, 1985.
266. Yasin Z, Quick D, Thiagarajan P, et al: Light-chain paraproteins with lupus anticoagu- 294. Rajkumar SV, Fonseca R, Lacy MQ, et al: Plasmablastic morphology is an independent
lant activity. Am J Hematol 62:99–102, 1999. predictor of poor survival after autologous stem-cell transplantation for multiple mye-
267. Zangari M, Saghafifar F, Anaissie E, et al: Activated protein C resistance in the absence loma. J Clin Oncol 17:1551–1557, 1999.
of factor V Leiden mutation is a common finding in multiple myeloma and is asso- 295. Hsu SM, Cossman J, Jaffe ES: Lymphocyte subsets in normal human lymphoid tissues.
ciated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis Am J Clin Pathol 80:21–30, 1983.
13:187–192, 2002. 296. San Miguel JF, Gutierrez NC, Mateo G, et al: Conventional diagnostics in multiple mye-
268. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory loma. Eur J Cancer 42:1510–1519, 2006.
multiple myeloma after single-agent thalidomide: Identification of prognostic factors in 297. Barlogie B, Alexanian R, Dixon D, et al: Prognostic implications of tumor cell DNA and
a phase 2 study of 169 patients. Blood 98:492–494, 2001. RNA content in multiple myeloma. Blood 66:338–341, 1985.
269. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple mye- 298. Bataille R, Robillard N, Pellat-Deceunynck C, et al: A cellular model for myeloma cell
loma. N Engl J Med 354:2079–2080, 2006. growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev 194:105–
270. Rajkumar SV, Blood E: Lenalidomide and venous thrombosis in multiple myeloma. N 111, 2003.
Engl J Med 354:2079–2080, 2006. 299. Harada H, Kawano MM, Huang N, et al: Phenotypic difference of normal plasma cells
271. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dex- from mature myeloma cells. Blood 81:2658–2663, 1993.
amethasone compared with dexamethasone alone in newly diagnosed multiple mye- 300. Rawstron AC, Orfao A, Beksac M, et al: Report of the European Myeloma Network on
loma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin multiparametric flow cytometry in multiple myeloma and related disorders. Haemato-
Oncol 24:431–436, 2006. logica 93:431–438, 2008.
272. Richardson PG, Blood E, Mitsiades CS, et al: A randomized phase 2 study of lenalido- 301. Van Camp B, Durie BG, Spier C, et al: Plasma cells in multiple myeloma express a
mide therapy for patients with relapsed or relapsed and refractory multiple myeloma. natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 76:377–382,
Blood 108:3458–3464, 2006. 1990.
273. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in 302. Robillard N, Avet-Loiseau H, Garand R, et al: CD20 is associated with a small mature
patients with multiple myeloma receiving thalidomide and chemotherapy. Blood plasma cell morphology and t(11;14) in multiple myeloma. Blood 102:1070–1071, 2003.
98:1614–1615, 2001. 303. Ocqueteau M, Orfao A, Garcia-Sanz R, et al: Expression of the CD117 antigen (c-Kit)
274. Zangari M, Siegel E, Barlogie B, et al: Thrombogenic activity of doxorubicin in myeloma on normal and myelomatous plasma cells. Br J Haematol 95:489–493, 1996.
patients receiving thalidomide: Implications for therapy. Blood 100:1168–1171, 2002. 304. Kumar S, Fonseca R, Dispenzieri A, et al: Bone marrow angiogenesis in multiple mye-
275. Minnema MC, Breitkreutz I, Auwerda JJ, et al: Prevention of venous thromboembolism loma: Effect of therapy. Br J Haematol 119:665–671, 2002.
with low molecular-weight heparin in patients with multiple myeloma treated with tha- 305. Barlogie B, Tricot G, Haessler J, et al: Cytogenetically defined myelodysplasia after mel-
lidomide and chemotherapy. Leukemia 18:2044–2046, 2004. phalan-based autotransplantation for multiple myeloma linked to poor hematopoietic
276. Baz R, Li L, Kottke-Marchant K, et al: The role of aspirin in the prevention of throm- stem-cell mobilization: The Arkansas experience in more than 3,000 patients treated
botic complications of thalidomide and anthracycline-based chemotherapy for multi- since 1989. Blood 111:94–100, 2008.
ple myeloma. Mayo Clin Proc 80:1568–1574, 2005. 306. Govindarajan R, Jagannath S, Flick JT, et al: Preceding standard therapy is the likely cause
277. Hirsh J: Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest of MDS after autotransplants for multiple myeloma. Br J Haematol 95:349–353, 1996.
131:275–277, 2007. 307. Konigsberg R, Zojer N, Ackermann J, et al: Predictive role of interphase cytogenetics
278. Larocca A, Cavallo F, Bringhen S, et al: Aspirin or enoxaparin thromboprophylaxis for survival of patients with multiple myeloma. J Clin Oncol 18:804–812, 2000.
for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 308. Seong C, Delasalle K, Hayes K, et al: Prognostic value of cytogenetics in multiple mye-
119:933–939; quiz 1093, 2012. loma. Br J Haematol 101:189–194, 1998.
279. Palumbo A, Cavo M, Bringhen S, et al: Aspirin, warfarin, or enoxaparin thrombo- 309. Tricot G, Sawyer JR, Jagannath S, et al: Unique role of cytogenetics in the prognosis of
prophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol
open-label, randomized trial. J Clin Oncol 29:986–993, 2011. 15:2659–2666, 1997.
280. Blade J, Lust JA, Kyle RA: Immunoglobulin D multiple myeloma: Presenting features, 310. Zojer N, Konigsberg R, Ackermann J, et al: Deletion of 13q14 remains an independent
response to therapy, and survival in a series of 53 cases. J Clin Oncol 12:2398–2404, adverse prognostic variable in multiple myeloma despite its frequent detection by inter-
1994. phase fluorescence in situ hybridization. Blood 95:1925–1930, 2000.
281. Krejci M, Buchler T, Hajek R, et al: Prognostic factors for survival after autologous 311. Ross FM, Avet-Loiseau H, Ameye G, et al: Report from the European Myeloma Net-
transplantation: A single centre experience in 133 multiple myeloma patients. Bone work on interphase FISH in multiple myeloma and related disorders. Haematologica
Marrow Transplant 35:159–164, 2005. 97:1272–1277, 2012.
282. Nair B, Waheed S, Szymonifka J, et al: Immunoglobulin isotypes in multiple myeloma: 312. Boccadoro M, Massaia M, Dianzani U, et al: Multiple myeloma: Biological and clinical
Laboratory correlates and prognostic implications in total therapy protocols. Br J Hae- significance of bone marrow plasma cell labelling index. Haematologica 72:171–175, 1987.
matol 145:134–137, 2009. 313. Drewinko B, Alexanian R, Boyer H, et al: The growth fraction of human myeloma cells.
283. Drayson M, Tang LX, Drew R, et al: Serum free light-chain measurements for identi- Blood 57:333–338, 1981.
fying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900– 314. Durie BG, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics, and prognosis
2902, 2001. in multiple myeloma. Blood 55:364–372, 1980.
284. Katzmann JA, Clark RJ, Abraham RS, et al: Serum reference intervals and diagnostic 315. Greipp PR, Witzig TE, Gonchoroff NJ, et al: Immunofluorescence labeling indices in
ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity myeloma and related monoclonal gammopathies. Mayo Clin Proc 62:969–977, 1987.
for detection of monoclonal light chains. Clin Chem 48:1437–1444, 2002. 316. Latreille J, Barlogie B, Dosik G, et al: Cellular DNA content as a marker of human mul-
285. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guide- tiple myeloma. Blood 55:403–408, 1980.
lines for serum-free light chain analysis in multiple myeloma and related disorders. 317. Latreille J, Barlogie B, Johnston D, et al: Ploidy and proliferative characteristics in
Leukemia 23:215–224, 2009. monoclonal gammopathies. Blood 59:43–51, 1982.
286. Dispenzieri A, Kyle RA, Katzmann JA, et al: Immunoglobulin free light chain ratio 318. Greipp PR, Lust JA, O’Fallon WM, et al: Plasma cell labeling index and beta 2-micro-
is an independent risk factor for progression of smoldering (asymptomatic) multiple globulin predict survival independent of thymidine kinase and C-reactive protein in
myeloma. Blood 111:785–789, 2008. multiple myeloma. Blood 81:3382–3387, 1993.
287. Rajkumar SV, Kyle RA, Therneau TM, et al: Serum free light chain ratio is an indepen- 319. Witzig TE, Gonchoroff NJ, Katzmann JA, et al: Peripheral blood B cell labeling indices
dent risk factor for progression in monoclonal gammopathy of undetermined signifi- are a measure of disease activity in patients with monoclonal gammopathies. J Clin
cance. Blood 106:812–817, 2005. Oncol 6:1041–1046, 1988.
288. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al: Prognostic value of serum free light 320. Dimopoulos MA, Kastritis E, Rosinol L, et al: Pathogenesis and treatment of renal fail-
chain ratio at diagnosis in multiple myeloma. Br J Haematol 137:240–243, 2007. ure in multiple myeloma. Leukemia 22:1485–1493, 2008.
289. Snozek CL, Katzmann JA, Kyle RA, et al: Prognostic value of the serum free light chain 321. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence Jones proteins. N
ratio in newly diagnosed myeloma: Proposed incorporation into the international stag- Engl J Med 324:1845–1851, 1991.
ing system. Leukemia 22:1933–1937, 2008. 322. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Pathogenesis and
290. van Rhee F, Bolejack V, Hollmig K, et al: High serum-free light chain levels and their prognostic implications. Arch Intern Med 150:1693–1695, 1990.
rapid reduction in response to therapy define an aggressive multiple myeloma subtype 323. Kyle RA, Greipp PR: Amyloidosis (AL). Clinical and laboratory features in 229 cases.
with poor prognosis. Blood 110:827–832, 2007. Mayo Clin Proc 58:665–683, 1983.
291. Bartl R, Frisch B, Fateh-Moghadam A, et al: Histologic classification and staging of 324. Buxbaum J: Mechanisms of disease: Monoclonal immunoglobulin deposition. Amy-
multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol loidosis, light chain deposition disease, and light and heavy chain deposition disease.
87:342–355, 1987. Hematol Oncol Clin North Am 6:323–346, 1992.

Kaushansky_chapter 107_p1733-1772.indd 1766 9/21/15 12:35 PM